ClinicalTrials.gg
CompletedNCT04508179Updated Nov 2, 2021

A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects

A Phase 1 interventional study of 7HP349 Single Ascending Dose and 7HP349 Multiple Ascending Dose in Solid Tumor, sponsored by 7 Hills Pharma, LLC. Completed at 1 site in United States. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-02.

Sponsored by 7 Hills Pharma, LLC · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Oct 2021, 5 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This study will evaluate the safety, tolerability and pharmacokinetics of 7HP349, an allosteric integrin activator, in healthy male subjects

Read the detailed description

This first-in-human (FIH) study consists of a placebo-controlled, sequential, dose escalation study to determine the safety, tolerability and pharmacokinetics (PK) of 7HP349 following single and multiple oral dose administration to healthy male subjects, with a separate, open-label food effect cohort at the optimal pharmacokinetic dose (OPD). The study will be carried out in 3 parts.

Part A: This is a placebo-controlled, within-cohort randomized, double-blind, sequential, single ascending dose (SAD) escalation study to determine the safety, tolerability and PK of 7HP349 following administration of single oral doses in healthy male subjects, and to define the OPD of 7HP349.

Part B: This is a placebo-controlled, within-cohort randomized, double-blind, sequential, multiple ascending dose (MAD) escalation study to determine the safety, tolerability and PK of 7HP349 following up to 5 once daily oral doses in healthy male subjects.

Part C: This is a randomized, open label, two-treatment, three-period, crossover study to evaluate the effect of the fed or fasting prandial state on the single dose PK of 7HP349.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

7 Hills Pharma, LLC is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males between the ages of 18 and 45 years, inclusive
  • Normal clinical chemistry, hepatic function, hematology, thyroid function
  • (BMI) of 19 to 30 kg/m2 inclusive and body weight not less than 60 kg
  • Agree to refrain from consuming products containing grapefruit, pomelo, star fruit or Seville oranges for at least 7 days before the first dose of study drug until the final discharge evaluation
  • Positive immune status as defined in serum as measles, mumps, varicella-zoster viruses (VZR); Antibody Index (AI) ≥ 1.1, and positive Rubella: AI ≥ 1.0

Exclusion criteria

Exclusion Criteria:

  • history of disorders, infections or drug as determined by the Investigator
  • History of , with the exception of cured basal cell or squamous cell carcinoma of the skin
  • Positive blood screen for (HIV), surface antigen (HBsAg), or antibody
  • Current treatment or treatment within 30 days with another medication
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    7HP349 Capsules

    Part A: 7HP349 Capsules (5 cohorts); Part B: 7HP349 Capsules (2 cohorts); Part C: 7HP349 Capsules (3-period cross-over)

    Drug: 7HP349 Single Ascending Dose · Drug: 7HP349 Multiple Ascending Dose · Drug: 7HP349 Food Effect

  • Placebo comparator
    Placebo Capsules

    Part A: Placebo Capsules (5 cohorts); Part B: Placebo Capsules (2 cohorts)

    Drug: Placebo Single Ascending Dose · Drug: Placebo Multiple Ascending Dose

Interventions

  • Drug7HP349 Single Ascending Dose

    Part A: 7HP349 Capsules, Single Ascending Dose (SAD)

    Also known as: 7HP349 SAD

  • Drug7HP349 Multiple Ascending Dose

    Part B: 7HP349 Capsules, Multiple Ascending Dose (MAD)

    Also known as: 7HP349 MAD

  • DrugPlacebo Single Ascending Dose

    Part A: Placebo Capsules, Single Ascending Dose (SAD)

    Also known as: Placebo SAD

  • DrugPlacebo Multiple Ascending Dose

    Part B: Placebo Capsules, Multiple Ascending Dose (MAD)

    Also known as: Placebo MAD

  • Drug7HP349 Food Effect

    Part C: 7HP349 Capsules, Food Effect

    Also known as: 7HP349 FE

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of 7HP349 in healthy male subjects as assessed by incidence of treatment-emergent adverse events according to CTCAE v5.0 criteria

    Safety assessments will include evaluation of incidence of treatment-emergent adverse events (AEs) according to CTCAE v5.0 criteria, including vital signs, resting electrocardiogram (ECG) parameters, standard hematology, chemistry, urinalysis and other tests

    Time frame: 17 days

Secondary outcomes

  1. Pharmacokinetics of 7HP349 in healthy male subjects as assessed by maximum plasma concentration (Cmax) towards determination of the optimal pharmacokinetic dose (OPD)

    Determination of maximum plasma concentration (Cmax)

    Time frame: 17 days

  2. Pharmacokinetics of 7HP349 in healthy male subjects as assessed by plasma exposure (AUClast and/or AUCinf) towards determination of the optimal pharmacokinetic dose (OPD)

    Determination of plasma exposure (AUClast and/or AUCinf)

    Time frame: 17 days

  3. Pharmacokinetics of 7HP349 in healthy male subjects as assessed by exposure in urine towards determination of the optimal pharmacokinetic dose (OPD)

    Determination of exposure in urine

    Time frame: 17 days

  4. Pharmacokinetics of 7HP349 in healthy male subjects as assessed by renal clearance (CLr) towards determination of the optimal pharmacokinetic dose (OPD)

    Determination of renal clearance (CLr)

    Time frame: 17 days

  5. Effect of food on the pharmacokinetics of 7HP349 in healthy male subjects as assessed by measurement of maximum plasma concentration (Cmax) in fed individuals

    Fed prandial state, determination of maximum plasma concentration (Cmax)

    Time frame: 28 days

  6. Effect of food on the pharmacokinetics of 7HP349 in healthy male subjects as assessed by measurement of maximum plasma exposure (AUClast and/or AUCinf) in fed individuals

    Fed prandial state, determination of plasma exposure (AUClast and/or AUCinf)

    Time frame: 28 days

  7. Effect of food on the pharmacokinetics of 7HP349 in healthy male subjects as assessed by measurement of maximum plasma concentration (Cmax) in fasted individuals

    Fasted prandial state, determination of maximum plasma concentration (Cmax)

    Time frame: 28 days

  8. Effect of food on the pharmacokinetics of 7HP349 in healthy male subjects as assessed by measurement of maximum plasma exposure (AUClast and/or AUCinf) in fasted individuals

    Fasted prandial state, determination of plasma exposure (AUClast and/or AUCinf)

    Time frame: 28 days

  9. Effect of food on the pharmacokinetics of 7HP349 in healthy male subjects as assessed by measurement of the Geometric Mean Ratio (GMR) of the maximum plasma concentration (Cmax) in fed vs. fasted individuals

    Determination of Geometric Mean Ratio (GMR) of fed:fasted Cmax

    Time frame: 28 days

  10. Effect of food on the pharmacokinetics of 7HP349 in healthy male subjects as assessed by measurement of the Geometric Mean Ratio (GMR) of the plasma exposure (AUClast and/or AUCinf) in fed vs. fasted individuals

    Determination of Geometric Mean Ratio (GMR) of fed:fasted AUClast and/or AUCinf

    Time frame: 28 days

07

Study locations

1 site
  • Frontage Clinical Services Inc.
    Secaucus, New Jersey 07094, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Oct 2021, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2020
First posted
Aug 11, 2020
StartActual
Oct 28, 2020
Primary completionActual
Oct 25, 2021
CompletionActual
Oct 25, 2021
Last update
Nov 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04508179
Lead sponsor
7 Hills Pharma, LLC
Collaborators
Frontage Clinical Services, Inc.
Responsible party
Sponsor
First posted
Aug 11, 2020
Start date
Oct 28, 2020
Primary completion
Oct 25, 2021
Completion
Oct 25, 2021
Last update
Nov 2, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion